Thermo Fisher Scientific Inc. News
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
see moreThermo Fisher Scientific Inc. Market News
10d
Thermo Fisher Scientific Posts Strong Q3 2026 Results, Launches FDA‑Cleared Autoimmune Test Amid Innovation Push
- Thermo Fisher reported Q3 2026 revenue of $12.14 billion and adjusted EPS of $6.68, backed by new product launches including an FDA‑cleared EliA CTD 13 autoimmune test.
17d
Thermo Fisher Rolls Out Proteomics Discoveries and Highlights Biologics Support at CPHI Milan
Thermo Fisher this week unveiled over 2,500 new biological associations via its proteomics tech and showcased enhanced drug development tools at CPHI Milan.
24d
Thermo Fisher Scientific Schedules Q3 Earnings Call for October 21
Thermo Fisher Scientific (TMO) has scheduled its third‑quarter 2026 earnings conference call for October 21, offering investors timely insight into performance amid recent strategic developments.
03 Oct at 14:36
Thermo Fisher Schedules Q3 2026 Earnings Call Amid Continued Momentum in Diagnostics and Bioprocessing
Thermo Fisher Scientific confirms its third‑quarter 2026 earnings call for October 21 and highlights recent diagnostics and media launches boosting innovation.
26 Sep at 14:36
Thermo Fisher Rolls Out New Gibco™ CHO‑K1 Media Panel to Accelerate Biologics Development
Thermo Fisher introduces Gibco™ CHO‑K1 catalog panel media and feed on Sept 23, 2026, aimed at expediting biologics development with enhanced cell culture solutions.
19 Sep at 14:36
Thermo Fisher Scientific CEO to Present at Morgan Stanley Healthcare Conference on September 15
Thermo Fisher Scientific (TMO) will feature CEO Marc Casper’s presentation at Morgan Stanley’s 24th Annual Global Healthcare Conference on September 15, offering insight into its strategic outlook.
12 Sep at 14:36
Thermo Fisher to Present at Morgan Stanley’s Global Healthcare Conference on September 15
Thermo Fisher Scientific confirmed its participation in Morgan Stanley’s 24th Annual Global Healthcare Conference on September 15, spotlighting investor engagement in its diagnostics and life‑science initiatives.